Immunophotonics founders and NCI SBIR staff outline practical steps for launching and funding a biotech startup

Billy Baza, program director at the National Cancer Institute’s Small Business Innovation Research (NCI SBIR) Development Center, hosted an Innovation Lab podcast episode focused on practical advice for early-stage biotech companies.

Lou Alloruzzo, chief executive officer of Immunophotonics, said building the “right network and relationships” was central to moving academic technology toward clinical trials and commercialization. He recommended assembling complementary talent, identifying mentors and advisors, and creating an initial strategic framework—what he called a concise set of foundational slides—that guides the company’s early decisions. “Trust” with collaborators and mentors, he said, is essential to that process.

David Anderson, chief scientific officer at Immunophotonics, said founders should define the target product profile—the intended clinical label, dose, toxicities and patient population—and work backward to design studies that prove those claims. That approach, he said, focuses limited funds on the experiments most relevant to regulatory filings and investor interest. “If you don’t know you have a compound that works in a specific indication, you don’t really have a potential product,” Anderson said.

Both guests discussed funding strategies. Lou described a mix of early-stage sources—angel investors and incubators (he named Biogenerator), venture funds and non-dilutive grants such as SBIR awards—and said Immunophotonics has secured more than $40,000,000 from various sources to advance its immuno-oncology program. Anderson described SBIR grants as “a non-dilutive source of money that allows you to derisk your program” and noted that receiving SBIR funding can signal validation to other investors.

Billy Baza summarized NCI SBIR’s support offerings, noting a four-phase SBIR pathway that, if fully followed, can represent roughly $7,000,000 in funding across phases. He also highlighted a newly launched STEP program to help applicants prepare stronger applications.

Panelists emphasized operational discipline and choosing outside partners carefully. Anderson urged teams to vet CDMOs and CROs by seeking references and interviewing both senior decision-makers and the people who will do the day-to-day work. Lou recommended committing to a single project-management system company-wide and described FounderSuite as a useful tool for tracking investor outreach and tying communications to individual stakeholders.

The founders also described strategic pivots. Lou said Immunophotonics initially worked on its own tumor-destruction device and a combination product but shifted after clinician feedback to a strategy focused on augmenting existing tumor-destruction techniques with an immunotherapy approach. He framed the pivot as a costly, two-year reset that ultimately improved product–market fit and investor alignment.

The episode closed with Baza directing listeners to sbir.cancer.gov for funding opportunities and commercialization resources and noting that this discussion will continue in a second episode.

What this means: Early-stage biotech founders should prioritize a clear, regulator-informed development plan, build broad and trusted networks, use tools to track investor relationships, consider SBIR as both funding and validation, and be prepared to pivot based on end-user feedback. The podcast signals resources available from NCI SBIR but does not record formal commitments or decisions by the agency.